{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:46:23Z","timestamp":1783741583687,"version":"3.55.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamaoto.2020.1340","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T15:32:24Z","timestamp":1593703944000},"page":"748","source":"Crossref","is-referenced-by-count":24,"title":["Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation"],"prefix":"10.1001","volume":"146","author":[{"given":"Ken","family":"Kazahaya","sequence":"first","affiliation":[{"name":"Department of Pediatric Otolaryngology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Department of Otorhinolaryngology\u2013Head and Neck Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara K.","family":"Prickett","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A.","family":"Paulson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington (UW) Medical Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Manning","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin R.","family":"Rudzinski","sequence":"additional","affiliation":[{"name":"Department of Laboratories, Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Rastatter","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology\u2013Head & Neck Surgery, Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"},{"name":"Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fred Hutchinson Cancer Research Center, Seattle Children\u2019s Hospital, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia S.","family":"Brose","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2013Head and Neck Surgery, University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Department of Pediatrics, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"orv200006r1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1089\/thy.2014.0460","article-title":"Management guidelines for children with thyroid nodules and differentiated thyroid cancer.","volume":"25","author":"Francis","year":"2015","journal-title":"Thyroid"},{"issue":"6","key":"orv200006r2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"10","key":"orv200006r3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/js.2018-00180","article-title":"Navigating systemic therapy in advanced thyroid carcinoma: from standard of care to personalized therapy and beyond.","volume":"2","author":"Rao","year":"2018","journal-title":"J Endocr Soc"},{"issue":"1","key":"orv200006r4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","article-title":"Novel targeted therapies and immunotherapy for advanced thyroid cancers.","volume":"17","author":"Naoum","year":"2018","journal-title":"Mol Cancer"},{"issue":"11","key":"orv200006r7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1089\/thy.2018.0064","article-title":"Response to lenvatinib in children with papillary thyroid carcinoma.","volume":"28","author":"Mahajan","year":"2018","journal-title":"Thyroid"},{"issue":"4","key":"orv200006r8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/thy.2008.0429","article-title":"The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.","volume":"19","author":"Waguespack","year":"2009","journal-title":"Thyroid"},{"issue":"11","key":"orv200006r10","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2015-3989","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer.","volume":"101","author":"Robinson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"orv200006r19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children.","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"orv200006r20","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090723","article-title":"Thyroid cancer in the pediatric population.","volume":"10","author":"Paulson","year":"2019","journal-title":"Genes (Basel)"},{"issue":"11","key":"orv200006r21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1089\/thy.2019.0041","article-title":"A novel ALK fusion in pediatric medullary thyroid carcinoma.","volume":"29","author":"Hillier","year":"2019","journal-title":"Thyroid"},{"key":"orv200006r5","author":"Taylor","year":"2019"},{"key":"orv200006r6","author":"Wirth","year":"2019"},{"key":"orv200006r9","unstructured":"Phase 1\/2 study of the highly-selective RET inhibitor, pralsetinib (BLU-667), in patients with thyroid cancer, non\u2013small cell lung cancer, and other advanced solid tumors (ARROW). ClinicalTrials.gov identifier: NCT03037385. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03037385"},{"key":"orv200006r11","unstructured":"Phase 1\/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion\u2013positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03157128"},{"key":"orv200006r12","unstructured":"A study of oral LOXO-292 in pediatric patients with advanced solid or primary central nervous system tumors (LIBRETTO-121). ClinicalTrials.gov identifier: NCT03899792. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03899792"},{"key":"orv200006r13","unstructured":"Phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 (AcS\u00e9). ClinicalTrials.gov identifier: NCT02034981. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02034981"},{"key":"orv200006r14","unstructured":"Ceritinib in mutation and oncogene directed therapy in thyroid cancer. ClinicalTrials.gov identifier: NCT02289144. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02289144"},{"key":"orv200006r15","unstructured":"A roll over study of alectinib in patients with anaplastic lymphoma kinase (ALK)\u2013positive or rearranged during transfection (RET)\u2013positive cancer. ClinicalTrials.gov identifier: NCT03194893. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03194893"},{"key":"orv200006r16","unstructured":"Targeted therapy directed by genetic testing in treating pediatric patients with relapsed or refractory advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders (The Pediatric MATCH Screening Trial). ClinicalTrials.gov identifier: NCT03155620. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03155620"},{"key":"orv200006r17","unstructured":"Evaluation of efficacy, safety of vandetanib in patients with differentiated thyroid cancer (VERIFY). ClinicalTrials.gov identifier: NCT01876784. Accessed May 23, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01876784"},{"key":"orv200006r18","unstructured":"A study of cabozantinib compared with placebo in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy. ClinicalTrials.gov identifier: NCT03690388. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03690388"},{"key":"orv200006r22","unstructured":"Larotrectinib in treating patients with previously untreated TRK fusion solid tumors and TRK fusion relapsed acute leukemia. ClinicalTrials.gov identifier: NCT03834961. Accessed May 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03834961"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2767782\/jamaotolaryngology_kazahaya_2020_rv_200006_1597339395.18972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T15:01:43Z","timestamp":1597935703000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2767782"}},"subtitle":["Is It Time for a Paradigm Shift?"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2020.1340","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}